Trials / Completed
CompletedNCT04060290
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational study | Observational study of this study, no interventions involved |
Timeline
- Start date
- 2020-05-12
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
- First posted
- 2019-08-19
- Last updated
- 2024-02-28
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04060290. Inclusion in this directory is not an endorsement.